<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00377455</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 06-043</org_study_id>
    <secondary_id>Bosentan</secondary_id>
    <nct_id>NCT00377455</nct_id>
  </id_info>
  <brief_title>Placebo Controlled Trial of Bosentan in Scleroderma Patients</brief_title>
  <official_title>Placebo Controlled Trial of Bosentan vs Placebo in NYHA Class I/II Scleroderma Patients With Exercise Induced Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the drug Bosentan improves exercise
      tolerance in scleroderma patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary hypertension (PAH) is a common and usually fatal form of lung disease in systemic
      sclerosis (SSc). Multiple drugs have been approved for the treatment of New York Heart
      Association (NYHA)Class III/IV PAH in scleroderma. Bosentan is an endothelin-1 antagonist
      which showed significant improvement in distance walked during 12 week clinical trials in PAH
      patients (7). Therapy for asymptomatic systemic sclerosis patients diagnosed incidentally
      with PAH (World Health Organization (WHO) Functional Class I) remains controversial. We
      hypothesize that asymptomatic or minimally symptomatic patients with systemic sclerosis and
      normal resting pulmonary artery pressures who demonstrate an abnormal rise in pulmonary
      artery systolic pressure with stress Doppler echocardiography testing represent a subset of
      patients who already have pulmonary vascular disease and who are at risk for the development
      of severe PAH. We further hypothesize that early identification and treatment of such
      patients may retard the progression of that disease.

      Hypotheses:

        1. Stress echocardiography identifies early pulmonary vascular disease by detecting
           exercise-induced pulmonary hypertension in patients with systemic sclerosis.

        2. Treatment of exercise-induced PAH with Bosentan will lead to improved exercise endurance
           in patients with systemic sclerosis.

      Subjects will be recruited from those patients who have had an abnormal exercise test as part
      of an earlier study, Exercise Echocardiograms in Scleroderma (IRB# 03-363).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was terminated due to inadequate enrolment
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Exercise Time on the Exercise Echocardiogram Using the Standard Bruce Stress Protocol.</measure>
    <time_frame>This will be determined after 16 weeks on the study medication.</time_frame>
    <description>The total exercise time measured using the exercise echocardiogram is evaluated with the standard Bruce Stress Protocol, and this will be determined after 16 weeks on the study medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-minute Walk Distance</measure>
    <time_frame>16 weeks</time_frame>
    <description>The distance walked during a 6-minute walk test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Natriuretic Peptide (BNP) Level</measure>
    <time_frame>16 weeks</time_frame>
    <description>Serum BNP level to evaluate Brain Natriuretic Peptide (BNP) level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelin-1(ET-1) Level</measure>
    <time_frame>16 weeks</time_frame>
    <description>From saved serum to determine Endothelian-1 (ET-1) levels in patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL)</measure>
    <time_frame>16 weeks</time_frame>
    <description>QOL is measured using the Short Form 36 Health Survey (SF-36, which measures health on eight dimensions: general health perception, physical and social functioning, role limitations by physical or emotional problems, mental health, vitality, and bodily pain. For each dimension items are coded, summed, and transformed on to a scale from 0 (worst health) to 100 (best health).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Systemic Scleroderma</condition>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Bosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan</intervention_name>
    <description>62.5 mg by mouth (PO) twice daily (Bid) for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks</description>
    <arm_group_label>Bosentan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>62.5 mg PO Bid for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  SSc patients &gt; 18 with NYHA functional Class I/II symptoms, informed consent, and who
             are willing to participate in the Pulmonary Hypertension Assessment and Recognition of
             Outcomes in Scleroderma (PHAROS) long term study (Georgetown IRB 04-227)

          -  Right heart catheterization with

               1. Normal Mean Pulmonary Arterial Pressure (PAP) at rest

               2. Mean PAP &gt; 30 with exercise

               3. Wedge Pressure &lt; 18

          -  Entry criteria for participating in the exercise echocardiogram study (Georegtown IRB
             03-363)

               1. Diffusing Capacity (DLCO) &lt;60 with a Forced Vital Capacity (FVC) &gt;60%, or

               2. FVC/DLCO &gt; 1.6, or

               3. a resting Pulmonary Arterial Systolic Pressure (PASP)&gt; 40mmHg

        Exclusion Criteria:

          -  Established resting pulmonary hypertension

          -  Congestive heart failure

          -  Diastolic dysfunction

          -  Pregnancy

          -  Inability to adequately walk/exercise

          -  Severe liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginia D Steen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Connecticut</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum. 1986 Apr;29(4):515-24.</citation>
    <PMID>3707629</PMID>
  </reference>
  <reference>
    <citation>Yousem SA. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol. 1990 May;21(5):467-74. Review.</citation>
    <PMID>2186993</PMID>
  </reference>
  <reference>
    <citation>al-Sabbagh MR, Steen VD, Zee BC, Nalesnik M, Trostle DC, Bedetti CD, Medsger TA Jr. Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study. J Rheumatol. 1989 Aug;16(8):1038-42.</citation>
    <PMID>2585400</PMID>
  </reference>
  <reference>
    <citation>MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J, Black CM. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford). 2001 Apr;40(4):453-9.</citation>
    <PMID>11312386</PMID>
  </reference>
  <reference>
    <citation>Grünig E, Janssen B, Mereles D, Barth U, Borst MM, Vogt IR, Fischer C, Olschewski H, Kuecherer HF, Kübler W. Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation. 2000 Sep 5;102(10):1145-50.</citation>
    <PMID>10973844</PMID>
  </reference>
  <reference>
    <citation>Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003 Feb;48(2):516-22.</citation>
    <PMID>12571862</PMID>
  </reference>
  <reference>
    <citation>Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 Mar 21;346(12):896-903. Erratum in: N Engl J Med 2002 Apr 18;346(16):1258.</citation>
    <PMID>11907289</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2006</study_first_submitted>
  <study_first_submitted_qc>September 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2006</study_first_posted>
  <results_first_submitted>March 28, 2011</results_first_submitted>
  <results_first_submitted_qc>June 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 20, 2011</results_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Georgetown University</investigator_affiliation>
    <investigator_full_name>Virginia Steen, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>scleroderma</keyword>
  <keyword>systemic sclerosis</keyword>
  <keyword>bosentan</keyword>
  <keyword>pulmonary hypertension</keyword>
  <keyword>PHAROS</keyword>
  <keyword>PHROS</keyword>
  <keyword>exercise echocardiogram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bosentan and Placebo Arms</title>
          <description>This group consists of subjects on both arms of the study - bosentan and placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bosentan and Placebo Arms</title>
          <description>This group consists of subjects on both arms of the study - bosentan and placebo</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Exercise Time on the Exercise Echocardiogram Using the Standard Bruce Stress Protocol.</title>
        <description>The total exercise time measured using the exercise echocardiogram is evaluated with the standard Bruce Stress Protocol, and this will be determined after 16 weeks on the study medication.</description>
        <time_frame>This will be determined after 16 weeks on the study medication.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bosentan/Placebo</title>
            <description>Outcomes not available, due to early termination of study</description>
          </group>
        </group_list>
        <measure>
          <title>Total Exercise Time on the Exercise Echocardiogram Using the Standard Bruce Stress Protocol.</title>
          <description>The total exercise time measured using the exercise echocardiogram is evaluated with the standard Bruce Stress Protocol, and this will be determined after 16 weeks on the study medication.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6-minute Walk Distance</title>
        <description>The distance walked during a 6-minute walk test.</description>
        <time_frame>16 weeks</time_frame>
        <population>Outcomes not available, due to early termination of study</population>
        <group_list>
          <group group_id="O1">
            <title>Bosentan/Placebo</title>
            <description>Outcomes not available, due to early termination of study</description>
          </group>
        </group_list>
        <measure>
          <title>6-minute Walk Distance</title>
          <description>The distance walked during a 6-minute walk test.</description>
          <population>Outcomes not available, due to early termination of study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brain Natriuretic Peptide (BNP) Level</title>
        <description>Serum BNP level to evaluate Brain Natriuretic Peptide (BNP) level</description>
        <time_frame>16 weeks</time_frame>
        <population>Outcomes not available, due to early termination of study</population>
        <group_list>
          <group group_id="O1">
            <title>Bosentan/Placebo</title>
            <description>Outcomes not available, due to early termination of study</description>
          </group>
        </group_list>
        <measure>
          <title>Brain Natriuretic Peptide (BNP) Level</title>
          <description>Serum BNP level to evaluate Brain Natriuretic Peptide (BNP) level</description>
          <population>Outcomes not available, due to early termination of study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endothelin-1(ET-1) Level</title>
        <description>From saved serum to determine Endothelian-1 (ET-1) levels in patients</description>
        <time_frame>16 weeks</time_frame>
        <population>Outcomes not available, due to early termination of study</population>
        <group_list>
          <group group_id="O1">
            <title>Bosentan/Placebo</title>
            <description>Outcomes not available, due to early termination of study</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelin-1(ET-1) Level</title>
          <description>From saved serum to determine Endothelian-1 (ET-1) levels in patients</description>
          <population>Outcomes not available, due to early termination of study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (QOL)</title>
        <description>QOL is measured using the Short Form 36 Health Survey (SF-36, which measures health on eight dimensions: general health perception, physical and social functioning, role limitations by physical or emotional problems, mental health, vitality, and bodily pain. For each dimension items are coded, summed, and transformed on to a scale from 0 (worst health) to 100 (best health).</description>
        <time_frame>16 weeks</time_frame>
        <population>Outcomes not available, due to early termination of study</population>
        <group_list>
          <group group_id="O1">
            <title>Bosentan/Placebo</title>
            <description>Outcomes not available, due to early termination of study</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life (QOL)</title>
          <description>QOL is measured using the Short Form 36 Health Survey (SF-36, which measures health on eight dimensions: general health perception, physical and social functioning, role limitations by physical or emotional problems, mental health, vitality, and bodily pain. For each dimension items are coded, summed, and transformed on to a scale from 0 (worst health) to 100 (best health).</description>
          <population>Outcomes not available, due to early termination of study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious or Other (non-serious) Adverse Events were collected/assessed, but none observed</desc>
      <group_list>
        <group group_id="E1">
          <title>Bosentan and Placebo Arms</title>
          <description>This group consists of subjects on both arms of the study - bosentan and placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Virginia Steen</name_or_title>
      <organization>Georgetown University</organization>
      <phone>202-444-6200</phone>
      <email>steenv@georgetown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

